Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Trial Profile

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Suspended
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Immunodeficiency disorders; Inflammation
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 18 Oct 2018 Status changed from recruiting to suspended.
    • 03 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Jul 2018 to 6 Jul 2018.
    • 28 Jun 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 26 Jun 2018 to 4 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top